Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	53.44	96.62	34.65	37.74
Short-Term Investments	158.24	189.36	22.9	13.59
Cash & Short-Term Investments	211.68	285.98	57.54	51.32
Cash Growth	-38.86%	396.98%	12.12%	-
Other Current Assets	2.65	4.62	3.12	1.93
Total Current Assets	214.33	290.6	60.66	53.25
Net Property, Plant & Equipment	7.58	10.66	10.61	12.44
Other Long-Term Assets	4.6	3.39	3.92	1.23
Total Assets	226.51	304.65	75.2	66.92
Accounts Payable	9.92	4.62	4.36	1.45
Accrued Expenses	26.3	25.19	12.58	8.23
Current Portion of Leases	3.58	3.94	2.92	2.28
Total Current Liabilities	39.79	33.76	19.86	11.95
Long-Term Leases	2.34	4.3	6.16	8.29
Other Long-Term Liabilities	-	-	-	0.01
Total Long-Term Liabilities	2.34	4.3	6.16	8.29
Total Liabilities	42.13	38.06	26.02	20.25
Additional Paid-in Capital	534.63	530	4.64	1.71
Accumulated Other Comprehensive Income	-0.02	0.11	0	-0.03
Retained Earnings	-350.24	-263.52	-136.04	-75.68
Total Common Shareholders' Equity	184.38	266.59	-131.4	-74
Minority Interest	-	-	180.57	120.67
Shareholders' Equity	184.38	266.59	49.18	46.68
Total Liabilities & Equity	226.51	304.65	75.2	66.92
Total Debt	5.92	8.24	9.08	10.56
Net Cash (Debt)	205.76	277.74	48.46	40.76
Net Cash Growth	-25.92%	473.08%	18.91%	-
Net Cash Per Share	4.76	7.25	71.94	89.48
Book Value	184.38	266.59	-131.4	-74
Book Value Per Share	4.27	6.95	-195.06	-162.46
Tangible Book Value	184.38	266.59	-131.4	-74
Tangible Book Value Per Share	4.27	6.95	-195.06	-162.46

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q